Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate
Scrip Pricing Debate

Sanofi Joins Peers, Will Make Lantus Available At $35 For All US Patients

Sanofi is the last of three big insulin makers to offer its top-selling insulin at the same out-of-pocket cost regardless of patients’ insurance coverage, but calls for other health care players to make concessions as well.

Market Access Pricing Strategies

IRA Drug Pricing Implications Impact Pharma Views On Deal Terms, Valuations

Pharma business development executives and venture capital investors shared their thoughts on the Inflation Reduction Act at Biocom’s Global Life Science Partnering and Investor Conference in San Diego.

Deals Financing

ICER’s Leqembi Assessment Inches Higher, Still Sees Eisai Price As Too High

The drug pricing watchdog said in its revised report that Alzheimer’s therapy Leqembi (lecanemab) meets cost-effectiveness thresholds at $8,900-$21,500, below Eisai/Biogen’s $26,500 list price.

Cost Effectiveness Pricing Strategies

For Some Biotechs, IRA Remains Intangible – For Now

Some biotech leaders say IRA policies don’t feel consequential yet, though small companies could face impacts from R&D and M&A decision making at big pharmas.

Deals Medicare

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Merck & Co. tells Scrip oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.

Commercial Deals

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: the best of J.P. Morgan; Novartis on its US-first commercial plan; Chugai CEO talks to Scrip on the Roche alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the global outlook for biopharma funding.

Business Strategies Commercial

Industry Looks At IRA Drawbacks And Silver Linings

Industry leaders are concerned about the outlook for small molecule drugs in particular, but execs at the J.P. Morgan Healthcare Conference were also optimistic there could be chances to shape the implementation of certain policies.

Pricing Debate Innovation

Stock Watch: Spanners In The Works For Q4 Results

While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.

Stock Watch Sales & Earnings

Scrip Asks… What Does 2023 Hold For Biopharma? Part 4: Pricing And Reimbursement

Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.

Scrip Asks Pricing Strategies

Stock Watch: J.P. Morgan Conference, Big Splash News And Stock Prices

Timing big M&A transactions to coincide with the biggest investor conference of the year is difficult. But getting it right can boost stocks across the sector.

Business Strategies Commercial

Scrip Asks…What Does 2023 Hold For Biopharma? Part 3: Global Headwinds

Headwinds of political instability, violent conflict, inflation and recession accompany us into 2023. Scrip surveyed industry leaders on the impacts for biopharma.

Scrip Asks Business Strategies

COVID-19 Windfalls Carry Pharma Into Stormy Times: Key Takeaways From Scrip 100 And Outlook 2023

The past couple of years have generated important growth for the pharma industry thanks to its drugs and vaccines for COVID-19. But with the IRA, high inflation, rising interest rates and chilly public markets, biopharma faces challenges this year. Here, we summarize key messages from In Vivo’s Outlook 2023.

Outlook 2023 Scrip 100
See All
UsernamePublicRestriction

Register